Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
$36.04
$1.93(2.32%)
At close: 4:00 PM EST
$36.04
$1.93(2.32%)
Day’s Range― - ―
52-Week Range$35.85 - $81.44
Previous CloseN/A
Volume3.65M
Average Volume (3M)22.87M
Market Cap
$156.31B
Enterprise Value$1.12T
Total Cash (Recent Filing)$26.96B
Total Debt (Recent Filing)$130.96B
Price to Earnings (P/E)14.6
Beta1.16
Next Earnings
May 06, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend Yield3.58%
Share Statistics
EPS (TTM)0.95
Shares Outstanding3,390,128,000
10 Day Avg. Volume17,980,355
30 Day Avg. Volume22,866,856
Financial Highlights & Ratios
PEG Ratio8.49
Price to Book (P/B)7.42
Price to Sales (P/S)4.84
P/FCF Ratio49.64
Enterprise Value/Market Cap7.16
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda6.97
Forecast
1Y Price Target
$43.00Price Target Upside19.31% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)3.22
Revenue Forecast (FY)$44.44B
Bulls Say, Bears Say
Bulls Say
Commercial Agreement With Online ResellerAnalyst notes that Hims' agreement to stop marketing compounded semaglutide and to offer FDA‑approved semaglutide removes a significant commercial headwind and could help restore branded product sales momentum.
Oral Product AdoptionAnalyst highlights strong prescription uptake for the oral Wegovy pill, signaling robust patient demand that expands the commercial opportunity beyond the injectable market.
Pricing Adjustments And Net Price ProtectionAnalyst states that list price reductions are designed to improve out‑of‑pocket affordability while not materially reducing net prices realized, which can support volume growth without a proportional revenue hit.
Bears Say
Competitive Pressure From RivalsAnalyst warns that intense competition from rival cardiometabolic and weight‑loss drugs, including recent commercial launches, is likely to erode market share and pressure sales of core products.
Patent And Exclusivity RiskAnalyst points out that loss of exclusivity for semaglutide could invite rapid branded competition and weigh on valuation as future revenue faces downward pressure.
Pipeline Uncertainty And Trial SetbacksAnalyst notes that lead pipeline candidates show promise but do not form a clear plan to replace semaglutide revenue, and some trials have underperformed, increasing uncertainty about long‑term growth.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $35.85 and its highest was $81.44 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $156.31B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 06, 2026 which is in 37 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 04, 2026. The company reported $0.954 earnings per share for the quarter, beating the consensus estimate of $0.923 by $0.031.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.412 which represents an annual dividend yield of 3.58%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.89.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.954 in its last earnings report, beating expectations of $0.923. Following the earnings report the stock price went down -6.183%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (19.31% Upside)
$43.00 (19.31% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 84%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 727.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Bullish
Bullish news 63%
Bearish news 38%
Bearish news 38%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.60%
12-Months-Change
Fundamentals
Return on Equity
61.10%
Trailing 12-Months
Asset Growth
31.99%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$43.00
▲(19.31% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.43% Mutual Funds
3.95% Other Institutional Investors
94.40% Public Companies and Individual Investors